Segall Bryant & Hamill LLC Acquires 503,713 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Segall Bryant & Hamill LLC raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 55.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,415,156 shares of the medical instruments supplier’s stock after purchasing an additional 503,713 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in AngioDynamics were worth $12,963,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Systematic Financial Management LP lifted its holdings in AngioDynamics by 14.3% during the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after purchasing an additional 300,785 shares during the last quarter. Royce & Associates LP raised its position in shares of AngioDynamics by 13.5% in the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock valued at $10,254,000 after purchasing an additional 133,312 shares during the period. Geode Capital Management LLC lifted its stake in shares of AngioDynamics by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier’s stock worth $7,477,000 after buying an additional 46,409 shares during the last quarter. State Street Corp boosted its holdings in shares of AngioDynamics by 2.7% during the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock worth $6,305,000 after buying an additional 21,218 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in AngioDynamics by 28.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after buying an additional 123,271 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Price Performance

ANGO stock opened at $10.18 on Wednesday. AngioDynamics, Inc. has a fifty-two week low of $5.30 and a fifty-two week high of $13.50. The stock has a market capitalization of $411.94 million, a price-to-earnings ratio of -1.81 and a beta of 0.56. The business’s fifty day moving average price is $10.57 and its two-hundred day moving average price is $8.76.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. During the same period last year, the firm earned ($0.05) earnings per share. AngioDynamics’s revenue for the quarter was down .1% compared to the same quarter last year. Research analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.